# Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

Study · id `cardio:ct-nct02942407` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02942407](<https://clinicaltrials.gov/study/NCT02942407>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02942407

Browse, organ or system: Heart; Kidneys  
Browse, condition area: Stroke; Heart rhythm problems; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

## Technical summary

Registry record NCT02942407. Randomized; no masking; primary purpose treatment. Start 2016-12 (actual); primary completion 2019-07-27 (actual). Results posted on 2020-12-29.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 154 participants (enrolled count; ClinicalTrials.gov record NCT02942407, source copy `cardio:ctgov-nct02942407-2020-12-29`, retrieved 2026-10-26)
- Started: 2016-12 (actual) (ClinicalTrials.gov record NCT02942407, source copy `cardio:ctgov-nct02942407-2020-12-29`, retrieved 2026-10-26)
- Primary completion: 2019-07-27 (actual) (ClinicalTrials.gov record NCT02942407, source copy `cardio:ctgov-nct02942407-2020-12-29`, retrieved 2026-10-26)
- Completion: 2019-08-12 (actual) (ClinicalTrials.gov record NCT02942407, source copy `cardio:ctgov-nct02942407-2020-12-29`, retrieved 2026-10-26)
- Results first posted: 2020-12-29 (ClinicalTrials.gov record NCT02942407, source copy `cardio:ctgov-nct02942407-2020-12-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02942407, source copy `cardio:ctgov-nct02942407-2020-12-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02942407-2020-12-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
- Acronym: RENAL-AF
- Condition: Atrial Fibrillation
- Condition: End Stage Renal Disease
- Intervention (Drug): apixaban
- Intervention (Drug): warfarin
- Lead sponsor: Christopher Granger, MD
- Lead sponsor class: OTHER
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial (`cardio:pubmed-36335914`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a880027884e85cb74de564355d561188a5d2cefc2b2e5c277fdceecfdc1b566d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
